ABSTRACT: The recent development of easily applicable fecal surrogate markers of intestinal inflammation, such as fecal calprotectin (FC), has provided a new means for objectively assessing disease activity in patients with chronic inflammatory bowel disease. Because the use of these markers is about to emerge, it is important to be aware of the possible limitations of measurements. We assessed levels of FC during bowel cleansing. In patients with high FC levels at baseline, the values measured during bowel cleansing varied considerably, remaining high or even returning to normal. Thus, stool sampling for FC assessment is not recommended during bowel preparation for colonoscopy.
†HUSLAB and Department of Clinical Chemistry, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.
Address correspondence and reprint requests to Kaija-Leena Kolho, MD, PhD, Children's Hospital, University of Helsinki, Box 281, FIN-00029 HUS, Finland (e-mail: email@example.com).
Received 9 March, 2012
Accepted 11 May, 2012
The study received grants from Finnish Pediatric Research Foundation Helsinki (K.L.K.) and University Central Hospital Research Fund (K.L.K.).
The authors report no conflicts of interest.